The XIENCE PRO Everolimus Eluting Coronary Stent System is indicated for improvingcoronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discretede novonativecoronary artery lesions.

- For restoring coronary flow in patients experiencing acute myocardial infarction whopresent within 12 hours of symptom onset.

- For the treatment of patients with concomitant diabetes, acute coronary syndrome,dual vessel lesions (two lesions in two different epicardial vessels), lesions residingwithin small coronary vessels; lesions where treatment results in the jailing of sidebranches (lesions with a side branch < 2 mm in diameter or an ostial stenosis< 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of bothmen and women.

- For the treatment of patients presenting with in-stent restenosis in coronary arterylesions; chronic total occluded coronary artery lesions (defined as coronary arterylesions with TIMI flow 0 and lasting longer than 3 months); and coronary arterybifurcation lesions.